Healthcare and Life Sciences Hot Topics: FDA Regulatory Considerations on Approvals for Artificial Intelligence

Washington, D.C. partners address FDA initiatives to modernize the marketing pathway for new products and the use of real world evidence for regulatory decision-making.

August 29, 2019

 

Washington, D.C. partners Ben Haas and Elizabeth Richards discuss the FDA’s efforts to modernize the regulatory pathway to marketing to account for artificial intelligence and machine learning in devices. In addition, they look at how FDA is viewing real world evidence and how it may be utilized for regulatory purposes.

 
 
Notice: We appreciate your interest in Latham & Watkins. If your inquiry relates to a legal matter and you are not already a current client of the firm, please do not transmit any confidential information to us. Before taking on a representation, we must determine whether we are in a position to assist you and agree on the terms and conditions of engagement with you. Until we have completed such steps, we will not be deemed to have a lawyer-client relationship with you, and will have no duty to keep confidential the information we receive from you. Thank you for your understanding.